Key message {#Sec1}
===========

In this study in French current practice on 294 lymphoma patients treated with the standard R-CHOP or R-CHVP protocols, low relative dose intensity was less often observed in teaching hospital than elsewhere. This suggests that even in a universal healthcare system, disparities in the management of diffuse large B-cell lymphoma patients' do exist according to the types of care center.

Background {#Sec2}
==========

Little is known about the mechanisms behind survival disparities according to many non-medical factors including age, ethnic group, socioeconomic status (SES), and place of residence observed in hematological malignancies. \[[@CR1]--[@CR10]\] Among lymphoma, one potential mechanism emerges from the results of studies among Hodgkin lymphoma (HL) \[[@CR11]\] and non-Hodgkin Lymphoma (NHL) \[[@CR12]--[@CR14]\] showing that socioeconomic factors, place of residence, and distance to the care center may affect access to treatment and treatment selection which was in turn related to survival. Another potential mechanism emerges from the results of studies dealing with the type of care provider and its consequence on survival. A population-based study of the Nebraska Lymphoma Study Group found a higher risk of death among high-risk lymphoma patients treated in rural university or community-based providers and urban community based provider compared to urban university-based providers. \[[@CR15]\] More recently, in a study based on an ongoing French regional cohort of diffuse large B cell lymphomas (DLBCL) treated with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) or RCHOP-derived regimens, the results showed that care facility type may influence overall survival and patients management. In this study, patients cared for in the regional public teaching hospital were more likely to receive the dose of chemotherapy initially planned by the medical team, i.e. the relative dose intensity (RDI). \[[@CR16]\] The ability to ensure a high RDI may be seen as a marker of high quality of care, as it is known to be associated with higher survival. \[[@CR17], [@CR18]\] To go further in the mechanisms linking the healthcare providers to survival, it remains uncertain whether better high RDI is only linked to a difference in patients' recruitment profiles across the various types of treatment provider or whether it also reflects real differences in cancer care and management practices. Indeed, in France the secondary care in oncology consists of private funding centers which can be nonprofit or for-profit and nonprofit public funding centers encompassing small community public hospitals to larger university affiliated hospitals. Moreover, in the French healthcare system, based on a universal access to care, patients are able to choose freely the hospital they wish to go to. Thus, although all patients may have access to specialized care, some patients could miss out on the best possible treatment because of high preference for proximity centers. \[[@CR19]\] This, with the fact that the academic or high-volume center are unlikely to be located outside large urban areas, may also lead to differences in the recruitment profiles of patients in the different types of care facility.

In the present study, we rule out both access to treatment and treatment selection issues by considering a sample of DLBCL patients all treated by standard protocols R-CHOP or R-CHVP (rituximab, cyclophosphamide, doxorubicin, etoposide, prednisone) each 21 days which constitutes a sample of patients globally homogeneous regarding the treatment their received \[[@CR20], [@CR21]\]. We aim to investigate whether and why RDI varies according to the types of care facility wherein patients were treated. Using data from French common practice, we try to disentangle the expression of patients' recruitment disparities between centers from the expression of differences in centers' features, which are assumed to be quite homogeneous for each type of care facility.

Method {#Sec3}
======

Study design and population {#Sec4}
---------------------------

The data were taken from the AMARE cohort, an ongoing prospective cohort of DLBCL patients in the Midi-Pyrénées region, the largest region of mainland France. This regional cancer network made up exclusively of cancer patients, including hematological malignancies, dictates that all e-medical files are systemically screened by disease-specific boards of experts during a multidisciplinary team meeting (MTM). Patients were identified by their presentation in MTM and were included in the AMARE cohort if they received first-line treatment for DLBCL with R-CHOP or R-CHOP-like regimens from November 2006 without age restriction, in the main centers covered by the regional cancer network: the public funding regional teaching hospital, five public funding community centers, and five private funding for-profit centers. The exclusion criteria were: central nervous system involvement, HIV infection, solid organ transplantation or previously documented indolent NHL. All patients signed an informed consent before inclusion in this network. The study was approved by the local ethics committee of the Toulouse teaching hospital. In the present study, we focused exclusively on patients treated by R-CHOP or R-CHVP which represented one on two patients treated for DLBCL of the initial AMARE cohort per types of care facility.

Data collection {#Sec5}
---------------

Data were collected by one person through direct examination of administrative and medical records of the 336 patients treated from November 2006--November 2013 (last follow-up in September 2014) who received the standard R-CHOP or R-CHVP protocols. During the follow-up, information was gathered regarding treatment-related events and vital status, including the date of the events. Care centers were pooled by type of care center: the public funding teaching hospital (Toulouse public funding University Hospital (UH)), the public funding community hospitals (CH), and the private funding for-profit hospitals (PH). Although these study deals with the data from 11 hospitals, we assume that the inter-facility type variability of the centers features are greater than the intra-facility type variability.

We collected patients' biomedical characteristics at diagnosis: age (continuous and in quartile); comorbidity (none or at least one among chronic or viral hepatitis, cardiovascular or metabolic disease, autoimmune disease or cancer); gender; the Ann Arbor stage, divided into localized (Ann Arbor stage I or II) or advanced (Ann Arbor stage III or IV); the ECOG performance status (PS) (PS of 0--4, with 1 being good and 4 being poor) \[[@CR22]\] and the serum lactate dehydrogenase concentration (normal or elevated (\>1)). We preferred using direct values of these parameters rather than crude categorization as IPI \[[@CR23], [@CR24]\] or NCCN-IPI \[[@CR25]\] scores that may introduce undesirable colinearity. We also noted the chemotherapy regimen at treatment initiation, which was described in detail elsewhere. \[[@CR21], [@CR26]--[@CR28]\] Regarding patients' socio-spatial characteristics, we used quintiles of the European ecological deprivation index (EDI) aggregated at the intra-municipalities level, built from patients' residential addresses at diagnosis as a proxy of their individual socioeconomic status. \[[@CR29]\] We assessed the travel distance by the road based on the fastest route in kilometers between the patient's residence and their care center and between the patient's residence and the teaching hospital coded in tertile to avoid making assumptions on any threshold. For each patient, the relative dose intensity (RDI) as described by Epelbaum et al. \[[@CR30]\], was assessed using the ratio between the dose intensity received and that initially planned at the treatment initiation. In this study, we calculated RDI for the principal drugs, i.e. cyclophosphamide and doxorubicin. After excluding patients who deceased or had tumor progression during the first-line treatment, patients who did not receive the whole initially planned dose intensity (RDI \< 100 %) were considered as having low RDI. Sensitivity analyzes were done using the continuous RDI value. Data regarding treatment-related toxicity events were documented by the total number of hospitalization days for toxicity over the first-line treatment period, but the dates of events were not available. The information regarding the cause concession was not available.

Statistical analysis {#Sec6}
--------------------

To study the factors influencing patients' repartition across the different types of care center, we built a multivariate multinomial logistic regression model by fixing the UH as the reference center to analyze the factors associated with being cared for in CH (model 1a) and in PH (model 1b). Then, we used multivariate logistic regression models with mixed effects to test for any center effect using the center as a random intercept. We tested the influence of the types of care providers on the probability of having low RDI without adjustment (model 2a) and after progressively adjusting for patients' biomedical characteristics (model 2b), socio-spatial characteristics (model 2c) and treatment-related toxicity events (model 2d). Our models included all variables associated with these outcomes in bivariate analyzes at the threshold of 0.2 (data not shown). The models were systematically adjusted for age, sex and socioeconomic status. All analyzes were done by using STATA release 12 (StataCorp LP, College Station, TX, USA). The cartography of patients and center distribution was performed using R \[[@CR31]\] and data from the French National Institute of Geography.

Results {#Sec7}
=======

In this study, we analyzed 294 patients who were alive at the treatment initiation and had complete data, which was about 87 % of the total number of the 336 patients treated by R-CHOP or R-CHVP. Compared to the included patients, those who were not included in the study belonged more often to the oldest age class, had more often advanced stage tumor, had poorest initial prognoses, and presented more often hospitalization for treatment-related toxicity and poor RDI. However they were evenly spread through the types of care facility (data not shown). The flowchart is given in Fig. [1](#Fig1){ref-type="fig"}. The characteristics of patients, disease and cancer management by types of care center are presented in Table [1](#Tab1){ref-type="table"}. Overall, the UH cared for younger patients with poorer initial prognosis, PH cared for patients with less comorbidity and better performance status, and CH cared for patients with more comorbidities and poorer performance status. Lastly, CH and PH tended to care for patients living in their vicinity, three out of four patients lived within a roughly 40 km radius, whereas patients cared for in the UH may have come from farther away. Moreover, patients cared for in PH or CH almost never lived nearer to the UH than the center where they were cared for. The map of patients' geographical distribution around the center where they are cared for is presented in supplemental file in the Fig. [2](#Fig2){ref-type="fig"} which illustrates patients' preferences for proximity centers and the capability of the UH to recruit both patients living near or far from the center.Fig. 1FlowchartTable 1Patients' characteristics and treatment adherence according to the care centers. *N* = 294TotalPHCHUH*n*%*n*%*n*%*n*%Patients' characteristicsGenderMale15352516234496848Female14148313836517452Age (tercile)t1 (until 59y)8830242920294431t2 (60y to 72y)15653404937537956t3 (73y and more)5017182213191913ComorbidityNone11740364426375539At least 117760465644638761Performance status (0 / 1--4)Normal234806782456412286Degraded6020151825362014Social deprivation indexHighly fav.6321182210143525Fav.4315141713191611Intermediate6823222718262820Dep.7425131619274230Highly dep.4616151810142115Nearest care centerUH119408100011178Other175607490701003122Distance (km) to the care centerMean (SD)38(59)23(30)28(29)51(76)Med \[q1-q3\]20\[7; 47\]12\[4;30\]24\[7; 39\]23\[10; 68\]Distance (km) to the teaching hospitalMean (SD)87(74)123(62)119(42)51(76)Med \[q1-q3\]75\[22; 137\]128\[69;176\]113\[81;155\]23\[10; 71\]Disease characteristicsStageI/II123*42*445426*37*5337III/IV171*58*38*46*44*63*8963LDH: lactate dehygrogenaseNormal163*55*50*61*49*70*6445Elevated131*45*32*39*21*30*7855B symptomsAbsence255*87*75*91*55*79*12588Presence39*13*7915*21*1712Cancer managementHospitalization for toxicityNone240*82*718744*63*12588At least 1 day54*18*111326*37*1712Relative dose intensity (RDI)Mean (SD)0.97(0.10)0.95(0.11)0.95(0.12)0.98(0.08)Med \[q1-q3\]1\[1; 1\]1\[0.9; 1\]1\[0.9; 1\]1\[1; 1\]Relative Dose Intensity (RDI)RDI = 100 %229*78*587150*71*121*85*RDI \< 100 %6522242920*29*21*15*Fig. 2Patients overall spatial distribution by care providers

Table [2](#Tab2){ref-type="table"} presents the factors associated with being cared for somewhere else than the UH. Compared with patients in the UH, those in CH were more likely to have degraded performance status, and better initial prognosis. These patients also tended to live in a less favorable socioeconomic area, more specifically they tended to live more often in favored (*p* = 0.033) areas than in highly favored areas. Compared with patients in the UH, those in PH were more likely to have earlier stage tumor, and to live less than 40 km from their care center. These patients also tended to have degraded performance status but this was not statistically significant with an alpha risk fixed at 5 % (*p*-value = 0.072),Table 2Factors associated with being cared for somewhere other than in the Toulouse public funding University Hospital (UH) among patients treated by standard regimens (RCHOP or RCHVP) (*n* = 294)Being cared for the public funding community hospitals (CH) instead of in UHBeing cared for in the private funding for-profit hospitals (PH) instead of in UHModel 1aModel 1bOR \[95 % CI\] *p-value*OR \[95 % CI\] *p-value*Age (tertile)t1 (until 59y)11t2 (60y to 72y)0.9\[0.4;1.9\]0.7770.9\[0.4;1.8\]0.749t3 (73y and more)1.3\[0.5;3.6\]0.5862.1\[0.8;5.2\]0.127GenderMen11Women0.9\[0.5;1.8\]0.8180.6\[0.4;1.2\]0.152ComorbidityNone11At least 11.2\[0.6;2.3\]0.6760.9\[0.5;1.7\]0.795Performance statusNormal11Degraded4.3\[1.9;9.5\]0.0002.2\[0.9;5.1\]0.072Distance to the care center (km)Up to 13 km1114 -- 41 km1.5\[0.7;3.3\]0.2960.5\[0.2;1.1\]0.070At least 42 km0.5\[0.2;1.3\]0.1580.2\[0.1;0.5\]0.000Social deprivation indexHighly favored11Favored3.2\[1.1;9.4\]0.0332.0\[0.7;5.2\]0.182Intermediate2.7\[1.0;7.6\]0.0541.8\[0.7;4.5\]0.184Deprived2.5\[0.9;6.7\]0.0730.7\[0.3;1.9\]0.519Highly deprived2.4\[0.7;7.5\]0.1431.6\[0.6;4.1\]0.370StageI/II11III/IV0.9\[0.4;1.7\]0.6450.5\[0.3;0.9\]0.026B symptomsAbsence11Presence1.6\[0.7;4.0\]0.2710.6\[0.2;1.7\]0.356Lactate dehydrogenaseNormal11Elevated0.3\[0.1;0.6\]0.0000.6\[0.3;1.2\]0.145Global *p*-values in model 1a age: *p* = 0.704, social deprivation index: *p* = 0.226, distance to the care center: *p* \< 0.055; in model 1b age: *p* = 0.135, social deprivation index: *p* = 0.186, distance to the care center: *p* = 0.001

Table [3](#Tab3){ref-type="table"} shows that being treated using the standard R-CHOP or R-CHVP protocols in UH rather than elsewhere was associated with lower rate of low RDI. After accounting successively for patients' biomedical characteristics, their socio-economical characteristics and distance to care center, low RDI was more frequent in PH than in UH (model 2c, OR \[95 % CI\] = 3.3 \[1.5; 7.1\]) and CH (model 2c, OR \[95 % CI\] = 2.6 \[1.2; 5.6\]). The adjustment for hospitalization for toxicities altered the OR associated with CH which became no more statistically significant (model 2d, OR \[95 % CI\] = 1.9 \[0.8; 4.4\]). We have tested the center effect using a random intercept which was not presented as its variance was smaller than 10^−8^ after adjustment for the type of care provider. This may translate the fact the center-related variations in the probability of low RDI was completely explained by the type of the care center. In addition, the models showed that an advanced stage at diagnosis and at least one day of hospitalization for toxicity were more likely to result in low RDI. No effects were noted for age, comorbidity, initial prognosis, social deprivation level, and distance to center. Similar results were obtained in sensitivity analyzes using RDI as a continuous variable (data not shown).Table 3Factors associated with having a low RDI (RDI \< 100 %) among DLBCL patients treated with CHOP21/RCHVP (*n* = 294)Model 2aModel 2bModel 2cModel 2dbeta \[95 % CI\] *p-value*beta \[95 % CI\] *p-value*beta \[95 % CI\] *p-value*beta \[95 % CI\] *p-value*Age56 -- 65 y11166 to 75y0.4\[0.2;0.8\]0.0080.4\[0.2;0.8\]0.0140.4\[0.2;0.8\]0.010At least 76y0.6\[0.2;1.4\]0.2060.6\[0.3;1.5\]0.2650.6\[0.2;1.4\]0.246GenderMen111Women1.4\[0.8;2.6\]0.2421.4\[0.8;2.6\]0.2331.4\[0.8;2.6\]0.251ComorbidityNone111At least 11.2\[0.6;2.2\]0.5721.2\[0.6;2.2\]0.6531.2\[0.6;2.3\]0.583Performance statusNormal111Degraded1.5\[0.7;3.1\]0.3101.4\[0.7;3.1\]0.3541.3\[0.6;2.9\]0.480StageI/II111III/IV1.4\[0.8;2.7\]0.2821.5\[0.8;2.8\]0.2111.5\[0.8;2.8\]0.235B symptomsAbsence111Presence1.4\[0.6;3.1\]0.4721.4\[0.6;3.2\]0.4411.2\[0.5;2.9\]0.626Lactate dehydrogenaseNormal111Elevated1.2\[0.7;2.3\]0.4911.1\[0.6;2.1\]0.6791.1\[0.6;2.0\]0.814Social deprivation indexHighly fav.11Favored0.6\[0.2;1.8\]0.4030.7\[0.2;2.0\]0.508Intermediate0.7\[0.3;1.7\]0.3870.7\[0.3;1.8\]0.444Deprived1.1\[0.5;2.7\]0.8421.1\[0.5;2.8\]0.815Highly dep.1.0\[0.4;2.6\]0.9931.0\[0.4;2.6\]0.935Distance to the care center (km)Up to 13 km1114 -- 40 km1.0\[0.5;2.1\]0.9951.2\[0.6;2.5\]0.687At least 41 km1.6\[0.7;3.3\]0.2661.5\[0.7;3.3\]0.323Hospitalization for toxicityNone1At least 1 day2.8\[1.4;5.7\]0.006Type of care centerUH1111CH2.3\[1.2;4.6\]0.0192.2\[1.0;4.8\]0.0392.6\[1.2;5.6\]0.0201.9\[0.8;4.4\]0.120PH2.4\[1.2;4.6\]0.0102.8\[1.4;5.6\]0.0053.3\[1.6;7.1\]0.0023.3\[1.5;7.1\]0.002All the models were adjusted for centre effect using a random intercept which is not presented as its variance in all the models was smaller than 10^−8^, this may be interpreted as a random intercept variance not statistically different from zero. Global *p*-values in model 2a type of care center: *p* \< 0.016; in model 2b age: *p* = 0.029, type of care center: *p* = 0.013; in model 2c age: *p* = 0.050, social deprivation index: *p* = 0.709, distance to the care center: *p* = 0.456, type of care center: *p* = 0.005; in model 2d age: *p* = 0.037, social deprivation index: *p* = 0.805, distance to the care center: *p* = 0.612, type of care center: *p* = 0.009

Discussion {#Sec8}
==========

This study, based on an ongoing cohort of DLBCL patients treated in the French Midi-Pyrénées region, shows an independent beneficial effect on RDI in the UH. PH, CH and UH cared for populations with different biomedical and socio-spatial characteristics. The former centers were more likely to treat patients living in their vicinity roughly within a 40 km radius. Patients treated in UH had more advanced stage and poorer initial prognosis without limitation regarding the distance from the residence to the care center. Patients' recruitment profile across the different types of care providers failed to explain the difference in RDI between UH and PH or CH. In this study among patients only treated with standard protocols, low RDI was less often observed in UH than elsewhere. This may translate a potentially greater quality in cancer care and management specific to this center, despite the universal healthcare system setting.

One of the main limitations of this study is that we cannot generalize our results to the national level and to other French teaching hospitals in general. However, this study dealt with the fourth more densely populated regions in France according to the French National Institute of Statistic and Economics Studies (INSEE) \[[@CR32]\] and the largest region of mainland France in terms of size. In addition, as is often observed in the rest of the country, regional healthcare is heterogeneously distributed around large urban area wherein multidisciplinary team meetings held in the UH centralize decisions regarding the management of both in- and outpatients, especially those needing intense treatment. At last, we excluded 42 patients from our analyzes because of missing data, decease or tumor progression during the treatment. These patients were evenly spread through the three center types. The comparison of the characteristics of included and excluded patients suggested that our sample overrepresented younger patients with less advanced stage tumor, better initial prognosis, less often hospitalization for toxicity and more often high RDI. The patients we studied would thus have a more favorable profile than those usually encountered in the current practice. We assume that caring patients with less favorable profile necessitate more discussion within the medical team and consequently it would be more affected by center-related disparity in cancer management.

This study has also several strengths. Few studies have explored the role of care provider types on treatment adherence in common practice in a universal healthcare system setting. We used a large (*n* = 294) DLBCL population homogeneously treated with the standard R-CHOP or R-CHVP protocols. Moreover, we collected data on biomedical and socio-spatial characteristics of patients, including the distance from residence to the reference center and to the care center where patients went, and treatments; this allowed us to study the effect of the types of care center among patients receiving the a same standard treatment.

Studies in solid tumors have already documented the influence of the care center characteristics on cancer care and patients outcomes. \[[@CR33]\] Some evidence mainly in the United States and Northern European countries supports the benefit of being cared for in high-volume or academic hospitals, such as improved survival in lung \[[@CR34]\] and colorectal cancers, \[[@CR35]\] and improved survival and adherence to the guidelines in ovarian \[[@CR36]\] and breast cancers. \[[@CR37], [@CR38]\] Regarding hematological malignancies, results from a population-based study in Nebraska showed a benefit of being cared for in urban university-based centers on survival among high risk lymphoma patients. \[[@CR15]\] In more recent studies, the type of care center was also linked to overall survival showing a benefit of being treated in high volume hospital among acute myeloid leukemia \[[@CR39]\] and DLBCL. \[[@CR16]\] However, the underlying mechanism remains unclear. In the present study, we showed that higher RDI observed in the UH was not due to patient's characteristics or treatment. This may suggest differential quality of care according to the center. The real stake is to identify what characteristics of the center may contribute to higher RDI in order to disseminate to the other centers and to ensure to all patients, whatever the center where are cared for, the best possible management of their cancer. Indeed, an organizational intervention has been implemented since 2006 among DLBCL patients treated in the UH of Midi-Pyrénées: an oncology-certified nurse systematically calls the patients during the treatment phase and collects clinical and biological observations, which are forwarded to the oncologist to enhance the care management and adherence to the treatment plan. \[[@CR40]\] Presently, the efficacy in reducing low RDI and the medico-economic evaluation of this nurse navigator procedure will be formally tested in a non-randomized-controlled study among several French teaching hospitals. We assume that such intervention may participate substantially to the mechanisms behind the higher RDI observed in the UH. In other clinical settings, studies have already given evidences of the benefits of nurse navigator interventions on cancer patients care management. \[[@CR41]--[@CR44]\] A possible solution may be to ensure such service for all patients across the region. However, other explanations are conceivable. For the past several years, studies have supported the existence of a noncompliance issue in medical oncology, pointing out the influence of physicians and care providers on adherence to the treatment plan was better in academic settings for both conventional \[[@CR45]\] and targeted chemotherapy. \[[@CR46]\] However, how the types of care providers may influence physician non-adherent behavior remains unclear. With regard to our study, we can rule out an effect of any lack of knowledge and weakness in clinician training as, regardless of the center where they practice, most of the clinicians have been trained by the Hematology Department of the UH. In addition, they regularly attend regional education sessions and national meetings which take place at least yearly. Another explanation might reside in the fact that reduction in treatment intensity outside academic settings may reflect more cautious care behavior among clinicians. Indeed, compared to clinicians in teaching hospitals, they may more frequently face frailer patients and limited facilities such as emergency or imaging units available 7 days a week and 24 h a day and therefore be inclined to reduce dose-intensity. Conversely, in the UH, the availability of facilities might encourage clinicians to not reduce dose-intensity which would be associated, at least in part, with an increase of hospitalization for toxicities. However, our results showed higher RDI in UH than PH even after controlling for hospitalization for toxicities. Moreover, hospitalizations for toxicities were more frequent in CH than elsewhere and adjustment for this variable altered the OR associated with CH which did not correspond to this explanation. In addition, the presence of the nurse navigator program in the UH may also encourage clinician to not reduce dose-intensity tendencies because it may provide a support to manage symptoms. This does not mean that the UH effect we observed is only the manifestation of the nurse navigator intervention, and we have to question whether such intervention would have been implemented elsewhere than in UH and with what outcome. Indeed, the "UH effect" on RDI we observed in this study may correspond to the expression of an enabling environment for developing innovative interventions. But whatever the reason, our results show differences between care centers that may be the consequence of different care management as potentially illustrated in UH. This point is major for us because it asks the question of how to insure the same quality of care everywhere on the French territory, which is an aim of the French health system.

Conclusion {#Sec9}
==========

This observational study in French common clinical practice shows that even in a universal healthcare system, disparities do exist in the management of DLCBL patients treated by standard protocols according to the types of care center. Although the fact that the treatment plan of all patients has been initially discussed in MTM which involves doctors among who most were trained at the same facility, we found management discrepancies related to the type of the care facility. Indeed, we found a higher adhesion to the treatment plan associated with being treated in the regional teaching hospital, not due to differences in recruited patients or in treatment provided. This suggests that at least in our study population, attempts at standardizing care using a medical outreach team, practice guidelines and clinician performance assessments might be not sufficient to ensure equal access to high-quality care. In addition, the place that teaching hospitals should occupy in the care landscape appears to be a critical issue. The dissemination of innovative organizational interventions such as for instance the nurse navigator developed for DLBCL patients in the Toulouse UH to non-academic centers might improve quality of care.
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